A Phase 3 interventional study of DE-109 440 μg in Non-Infectious Uveitis of the Posterior Segment of the Eye, sponsored by Santen Inc.. Completed at 25 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-12.
Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.
Among the 139 studies in Uveitis with a site in United States, this one is the 32nd largest by enrollment of the 100 interventional ones that give a count, is one of 5 that started in 2014, is one of 31 in phase 3, and was the 88th registered.
300 studies on the registry are indexed under Uveitis; 33 are open to participants now.
Browse Uveitis studies →7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages up to 17
Quan Dong Nguyen · Sites in United States
Ages 18–70
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
Meyer Children's Hospital IRCCS · Sites in United States, Belgium, Greece and 2 more countries
Ages 1–16
The Cleveland Clinic · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 40 · Phase 3 31 · Phase 4 9
First in 1987; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 30 across 175 interventional studies indexed under Uveitis.
Median enrollment 19 across the 100 interventional studies, 123 across the 36 observational. Of the 117 that completed or were terminated, 50 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 139 have an industry lead sponsor. The 10 most frequent:
This study is registered under Santen Inc., one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen Inc. is the lead sponsor of 32 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Santen Pharmaceutical Co., Ltd. has 3 studies filed under Uveitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Uveitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518134Jaeb Center for Health ResearchA Study of Uveitis in Children <18 Years of Age | 2027-04-01 |
| NCT04704609The Cleveland ClinicImaging Quantification of Inflammation (IQI) | 2027-04-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Uveitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA development program.
This is a multicenter, open-label, extension study of intravitreal injections of the 440 μg dose of DE-109 in subjects with non-infectious uveitis of the posterior segment who received any dose of DE-109 and exited the SAKURA program under Santen Protocol 32-007, Amendment 05.
Subjects who were randomized and received at least two injections of DE-109 during the first five months of the SAKURA program and obtained clinical benefit from the study medication, as determined by the Investigator, may be considered for entry in this 12-month extension study. The minimum time lag from last injection in the SAKURA program to entry into the current protocol is 60 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DE-109 440 μg
Drug: DE-109 440 μg
Medium Dose
Also known as: Sirolimus
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye
Best Corrected Visual Acuity (BCVA) measures the acuteness or clearness of best-corrected vision in ETDRS (Early Treatment of Diabetic Retinopathy Study) letters. An increase in BCVA indicates improvement in the best-corrected vision. A BCVA score of 85 ETDRS letters is equivalent to 20/20 vision, which is considered normal vision.
Time frame: Day 1 (Baseline) and Month 12 or early termination visit
Mean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye
Intraocular pressure (IOP), the fluid pressure inside the eye, was measured by applanation tonometry in millimeters mercury (mmHg) with one decimal point.
Time frame: Day 1 (Baseline) and Month 12 or early termination visit
Number of Subjects With a Shift in Choroid Status at Month 12 in the Study Eye.
Ophthalmoscopy findings were reported as normal or abnormal.
Time frame: Day 1 (Baseline) and Month 12 or early termination visit
Changes From Baseline in Vitreous Haze (VH) Scores at Month 12
Vitreous Haze (VH) scores were measured using the modified Standardized Uveitis Nomenclature Photographic Scale (SUN) : 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
Time frame: Day 1 (Baseline) and Month 12 or early termination visit
Number of Subjects Who Receive Rescue Therapy.
Rescue therapy was defined as any treatment that would have a therapeutic effect on the uveitis in the posterior segment (e.g., systemic treatment with an immunosuppressant agent, or a corticosteroid injection in the study eye) other than intravitreal DE-109 determined by the Investigator.
Time frame: By Month12
Number of Subjects With a Shift in Macula Status at Month 12 in the Study Eye.
Ophthalmoscopy findings were reported as normal or abnormal.
Time frame: Day 1 (Baseline) and Month 12 or early termination visit
Number of Subjects With a Shift in Optic Nerve Status at Month 12 in the Study Eye.
Ophthalmoscopy findings were reported as normal or abnormal.
Time frame: Day 1 (Baseline) and Month 12 or early termination visit
Number of Subjects With a Shift in Retina Status at Month 12 in the Study Eye.
Ophthalmoscopy findings were reported as normal or abnormal.
Time frame: Day 1 (Baseline) and Month 12 or early termination visit
| Milestone | DE-109 440 μg |
|---|---|
| Started | 60 |
| Completed | 43 |
| Not completed | 17 |
Best Corrected Visual Acuity (BCVA) measures the acuteness or clearness of best-corrected vision in ETDRS (Early Treatment of Diabetic Retinopathy Study) letters. An increase in BCVA indicates improvement in the best-corrected vision. A BCVA score of 85 ETDRS letters is equivalent to 20/20 vision, which is considered normal vision.
| ETDRS Letters | DE-109 440 μg |
|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye | 2.1 ± 11.35 |
Intraocular pressure (IOP), the fluid pressure inside the eye, was measured by applanation tonometry in millimeters mercury (mmHg) with one decimal point.
| mmHg | DE-109 440 μg |
|---|---|
| Mean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye | 0.3 ± 4.16 |
Ophthalmoscopy findings were reported as normal or abnormal.
| Subjects | DE-109 440 μg |
|---|---|
| Normal to Normal | 36 |
| Normal to Abnormal | 0 |
| Abnormal to Normal | 4 |
| Abnormal to Abnormal | 3 |
Vitreous Haze (VH) scores were measured using the modified Standardized Uveitis Nomenclature Photographic Scale (SUN) : 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
| score on a scale | DE-109 440 μg |
|---|---|
| Changes From Baseline in Vitreous Haze (VH) Scores at Month 12 | -0.09 ± 0.847 |
Rescue therapy was defined as any treatment that would have a therapeutic effect on the uveitis in the posterior segment (e.g., systemic treatment with an immunosuppressant agent, or a corticosteroid injection in the study eye) other than intravitreal DE-109 determined by the Investigator.
| Participants | DE-109 440 μg |
|---|---|
| Number of Subjects Who Receive Rescue Therapy. | 9 |
Ophthalmoscopy findings were reported as normal or abnormal.
| Subjects | DE-109 440 μg |
|---|---|
| Normal to Normal | 20 |
| Normal to Abnormal | 2 |
| Abnormal to Normal | 6 |
| Abnormal to Abnormal | 15 |
Ophthalmoscopy findings were reported as normal or abnormal.
| Subjects | DE-109 440 μg |
|---|---|
| Normal to Normal | 39 |
| Normal to Abnormal | 2 |
| Abnormal to Normal | 0 |
| Abnormal to Abnormal | 2 |
Ophthalmoscopy findings were reported as normal or abnormal.
| Subjects | DE-109 440 μg |
|---|---|
| Normal to Normal | 34 |
| Normal to Abnormal | 2 |
| Abnormal to Normal | 1 |
| Abnormal to Abnormal | 6 |
Collected over An on-study Adverse Events (AEs) were collected after the date of the written informed consent until the Last Study Visit at Month 12 or early termination visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DE-109 440 μg | 0/60 (0%) | 8/60 (13.3%) | 35/60 (58.3%) |
| Event | DE-109 440 μg |
|---|---|
| Intraocular Pressure IncreasedInvestigations | 2/60 |
| CataractEye disorders | 1/60 |
| Visual Acuity ReducedEye disorders | 1/60 |
| Vitreous HemorrhageEye disorders | 1/60 |
| Cerebrovascular AccidentNervous system disorders | 1/60 |
| Trigeminal NeuralgiaNervous system disorders | 1/60 |
| Cellulitis GangrenousInfections and infestations | 1/60 |
| Procedural ComplicationInjury, poisoning and procedural complications | 1/60 |
| Pathological FractureMusculoskeletal and connective tissue disorders | 1/60 |
| Lung Adenocarcinoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/60 |
| Event | DE-109 440 μg |
|---|---|
| UveitisEye disorders | 8/60 |
| Intraocular Pressure IncreasedInvestigations | 7/60 |
| Cystoid Macular OedemaEye disorders | 6/60 |
| Intermediate UveiEye disorders | 6/60 |
| IridocyclitisEye disorders | 3/60 |
| Macular FibrosisEye disorders | 3/60 |
| Intraocular Pressure DecreasedInvestigations | 3/60 |
| SinusitisInfections and infestations | 3/60 |
| Age, Continuous(years) | DE-109 440 μg |
|---|---|
| Mean | 43.31 ± 15.092 |
| Sex: Female, Male(Participants) | DE-109 440 μg |
|---|---|
| Female | 31 |
| Male | 29 |
| Race (NIH/OMB)(Participants) | DE-109 440 μg |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 21 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 30 |
| More than one race | 2 |
| Unknown or Not Reported | 2 |
| Race/Ethnicity, Customized(Participants) | DE-109 440 μg |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 47 |
| Not reported | 3 |
| Geographic Region(Participants) | DE-109 440 μg |
|---|---|
| United States | 33 |
| India | 17 |
| Europe, the Middle East and Africa | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Nov 2017, 37 months.
Results were first posted in Feb 2020, 2 years 3 months after primary completion.
Of 15 phase 3 interventional studies under Uveitis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus